New mRNA vaccines aim to stop brain cancer comeback
NCT ID NCT07520214
First seen Apr 18, 2026 · Last updated May 19, 2026 · Updated 2 times
Summary
This early-phase study tests two mRNA vaccines, GV-108 and GV-907, in 9 adults with a specific type of brain cancer (IDH-wildtype glioblastoma). The goal is to see if the vaccines are safe and can trigger the immune system to fight the cancer, potentially preventing it from coming back after standard treatment. Participants must have had complete tumor removal and no signs of recurrence before joining.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Tiantan Hospital
Beijing, Beijing Municipality, 100050, China
Conditions
Explore the condition pages connected to this study.